In a series of strategic advancements, SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company devoted to developing therapies for central nervous system disorders and rare diseases, has made significant strides in the past few months. These milestones emphasize the company’s commitment to enhancing its intellectual property portfolio, fostering innovative collaborations, and growing its market value.
MitoCareX Stake Sale Reflects Considerable Valuation Increase
In a move that showcases SciSparc’s shrewd investment strategy, the company recently signed a non-binding letter of intent to divest its stake in MitoCareX Bio. This prospective sale comes with an intended valuation that represents a remarkable 47% increase from the initial investment SciSparc made in MitoCareX. Such a significant valuation boost underscores SciSparc’s keen eye for high-growth potential investments within the biotechnology sphere.
Expanding Patent Portfolio with U.S. and European Approvals
SciSparc’s robust intellectual property portfolio received a substantial boost this year. On May 31, 2024, the European Patent Office granted a patent for SciSparc’s application
Comments